The global healthcare industry is rapidly evolving with the increasing adoption of advanced cell therapies, precision medicine, and immunotherapy treatments. Among the critical procedures supporting these innovations, leukapheresis has emerged as a highly essential blood component separation technology used in therapeutic and research applications.
Leukapheresis plays a major role in collecting white blood cells (leukocytes) from patients or donors for use in cancer therapies, stem cell transplantation, autoimmune disease treatment, and cell & gene therapy manufacturing. As the demand for CAR-T cell therapies and personalized medicine continues to rise globally, the leukapheresis market is witnessing substantial growth.
According to Kings Research, the global leukapheresis market was valued at USD 103.4 million in 2024 and is projected to reach USD 180.5 million by 2032, growing at a CAGR of 7.26% during the forecast period.
What is Leukapheresis?
Leukapheresis is a specialized medical procedure used to separate and collect white blood cells from blood. During the process, blood is withdrawn from the patient or donor, processed through an apheresis machine, and the targeted white blood cells are isolated while the remaining blood components are returned to the body.
The procedure is commonly used for:
- Leukemia treatment
- Cell and gene therapy manufacturing
- CAR-T therapy preparation
- Stem cell transplantation
- Immunotherapy research
- Autoimmune disease management
Leukapheresis is considered a crucial step in modern oncology and regenerative medicine because it provides high-quality cellular material required for advanced therapeutic applications.
Growing Adoption of Cell & Gene Therapies Driving Market Growth
One of the primary factors accelerating the leukapheresis market is the rapid expansion of cell and gene therapy development worldwide. CAR-T cell therapy, in particular, has created massive demand for leukocyte collection procedures.
Cell-based therapies require efficient collection of immune cells from patients before laboratory modification and reinfusion. As pharmaceutical and biotechnology companies expand their cell therapy pipelines, the need for reliable leukapheresis systems continues to grow significantly.
According to recent industry data, over 1,500 CAR-T cell therapy clinical trials are currently registered globally, highlighting the increasing dependence on leukapheresis procedures.
The rising focus on personalized medicine and immunotherapy is expected to further strengthen long-term market demand.
Rising Prevalence of Hematologic Disorders
The increasing prevalence of leukemia, lymphoma, autoimmune diseases, and blood disorders is another major growth driver for the leukapheresis market.
Healthcare providers increasingly utilize therapeutic leukapheresis to manage patients with elevated white blood cell counts and hematologic complications. The growing burden of cancer globally has significantly increased the adoption of advanced blood separation procedures.
Research studies indicate rising diagnosis rates of leukemia and other hematologic malignancies, which continue to drive demand for leukapheresis technologies in hospitals and cancer treatment centers.
Additionally, the increasing prevalence of autoimmune disorders such as rheumatoid arthritis and multiple sclerosis has created new opportunities for therapeutic apheresis applications.
Technological Advancements Enhancing Procedure Efficiency
Technological innovation is transforming the leukapheresis industry through the development of automated, safer, and more efficient apheresis systems.
Manufacturers are increasingly focusing on:
- Automated cell collection systems
- Closed-loop processing technology
- Continuous flow centrifugation systems
- Digital monitoring platforms
- High-efficiency disposable kits
- Enhanced patient safety mechanisms
Advanced leukapheresis devices improve:
- Cell yield accuracy
- Procedure consistency
- Patient comfort
- Workflow efficiency
- Safety compliance
Modern systems also reduce procedure times and improve collection quality, making them highly suitable for commercial-scale cell therapy manufacturing.
Market Segmentation Analysis
By Product
The market is segmented into:
- Devices
- Disposables
The devices segment currently dominates the market due to increasing installation of automated leukapheresis systems across hospitals, blood centers, and research institutions. Advanced systems with digital automation capabilities are witnessing high adoption globally.
Meanwhile, the disposables segment is expected to grow rapidly because of rising procedural volumes and increasing demand for sterile single-use consumables.
By Application
Based on application, the market includes:
- Therapeutic applications
- Research applications
The research segment is expected to witness strong growth due to increasing oncology research, immunology studies, and expanding clinical trial activity. The growing demand for cellular material in biopharmaceutical research is significantly boosting leukapheresis adoption.
Therapeutic applications also continue to expand due to increasing use in leukemia treatment and autoimmune disease management.
By End User
The major end users include:
- Hospitals & clinics
- Blood centers
- Academic & research institutes
- Biopharmaceutical companies
Hospitals and clinics account for a major market share due to high patient volumes and growing adoption of advanced therapeutic procedures.
Biopharmaceutical companies are also emerging as a fast-growing segment because leukapheresis is an essential component of cell therapy manufacturing workflows.
Regional Insights
North America
North America dominates the leukapheresis market due to:
- Strong healthcare infrastructure
- High clinical trial activity
- Early adoption of advanced therapies
- Presence of major biotechnology companies
- Increasing FDA approvals for CAR-T therapies
The United States remains a leading market because of its large oncology research ecosystem and advanced cell therapy manufacturing capabilities.
Asia-Pacific
Asia-Pacific is expected to register the fastest growth during the forecast period.
Countries such as China, India, Japan, and South Korea are rapidly expanding:
- Clinical research infrastructure
- Biopharmaceutical manufacturing
- Regenerative medicine investments
- Oncology treatment facilities
The increasing healthcare expenditure and growing focus on advanced therapeutics are creating substantial growth opportunities in the region.
Europe
Europe also represents a significant market due to increasing investments in cell and gene therapy research, supportive regulatory frameworks, and rising adoption of advanced apheresis systems.
Competitive Landscape
The leukapheresis market is highly technology-driven, with major players focusing on innovation, automation, and strategic collaborations.
Key companies operating in the market include:
- Terumo Corporation
- Haemonetics Corporation
- Asahi Kasei Group
- Miltenyi Biotec
- Charles River Laboratories
- Lonza Group AG
- Cerus Corporation
These companies are actively investing in:
- Automated leukapheresis platforms
- Cell therapy workflow optimization
- Digital integration technologies
- Manufacturing expansion
- Research partnerships
Strategic collaborations between healthcare institutions and biotechnology companies are expected to further accelerate market innovation.
Emerging Trends in the Leukapheresis Market
Several important trends are shaping the future of the market:
Expansion of CAR-T Therapy Manufacturing
The rapid commercialization of CAR-T therapies is significantly increasing leukapheresis demand globally.
Shift Toward Automated Systems
Healthcare facilities are increasingly adopting automated leukapheresis systems to improve procedural consistency and reduce manual errors.
Growth of Mobile Leukapheresis Centers
Portable and mobile collection centers are emerging to improve patient accessibility and streamline clinical trial operations.
Increasing Demand for Single-Use Disposable Kits
Stringent infection control standards are driving adoption of disposable leukapheresis components.
Challenges Affecting Market Growth
Despite strong growth potential, the market faces several challenges:
- High equipment costs
- Complex regulatory requirements
- Limited availability of trained professionals
- Infrastructure limitations in developing regions
- Procedural complexity
However, continuous technological advancements and rising investments in precision medicine are expected to address these barriers gradually.
Future Outlook
The future of the leukapheresis market appears highly promising as healthcare systems increasingly adopt advanced cell therapies and personalized treatment approaches.
The growing burden of cancer, rising investment in regenerative medicine, and expansion of clinical research activities will continue driving global demand. Technological advancements in automated apheresis systems and disposable solutions are expected to improve operational efficiency and support market expansion further.
As precision medicine becomes more mainstream, leukapheresis will remain a foundational technology in cell collection and therapeutic manufacturing workflows.
For detailed market insights, visit Kings Research Leukapheresis Market Report.
